In immunotherapy against lung cancer, including NSCLC, SCLC and other cancers

Inventors

SONG, Colette • Schoor, Oliver • FRITSCHE, Jens • Weinschenk, Toni • Singh, Harpreet

Assignees

Immatics Biotechnologies GmbH

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12275768-B2

Patent

Publication Date

2025-04-15

Expiration Date


Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Core Innovation

The document describes peptides and peptide-based pharmaceuticals centered on MHC-binding T-cell epitopes. Peptides are defined by specific amino acid sequences, including LTEAVLNRY (SEQ ID NO: 160), and are used in forms such as pharmaceutically acceptable salts. The peptides are presented as capable of immunological binding in the context of MHC class I and being recognized by CD8 T cells when bound.

The described subject matter extends to modified peptide forms, including pegylated peptides comprising LTEAVLNRY (SEQ ID NO: 160) or pharmaceutically acceptable salts thereof. Pharmaceutical compositions include the peptide or its salt in combination with a pharmaceutically acceptable carrier, and in some instances further include an adjuvant selected from a broad enumerated list.

The document also addresses how the peptide entities can be produced, including routes such as solid phase peptide synthesis or expression in a yeast cell or bacterial cell expression system. In addition to the peptide composition aspects, the document positions the peptide/MHC and CD8 T-cell recognition concept within immunological use cases, with support for therapeutic and imaging-related formats described in the partial content.

Claims Coverage

The partial content identifies two independent claims, with inventive feature themes spanning a specific peptide sequence in a pharmaceutically acceptable salt form and a pegylated version of the same peptide sequence with defined salt and composition coverage. The independent claims are supported by dependent claims that add immunological interaction constraints, salt selection, formulation carrier options, optional adjuvant selection, and permitted peptide production routes.

Peptide sequence in pharmaceutically acceptable salt form

A peptide consisting of the amino acid sequence LTEAVLNRY (SEQ ID NO: 160) in the form of a pharmaceutically acceptable salt.

Pegylated peptide of defined sequence

A pegylated peptide consisting of the amino acid sequence of LTEAVLNRY (SEQ ID NO: 160) or a pharmaceutically acceptable salt thereof.

Across the identified independent claims, the main claim coverage focuses on a defined LTEAVLNRY (SEQ ID NO: 160) peptide in salt form, and alternatively as a pegylated peptide, with dependent claim refinement directed to MHC class-I/CD8 T-cell recognition, specific salt choices, formulation with pharmaceutically acceptable carriers, optional adjuvants, and specified production routes.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Not explicitly described in patent.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.